-
52-week Open Label Safety-Tolerability Study
NCT07369154 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
NCT07615426 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
NCT07191483 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Study to Evaluate the Effect of KarXT on Urological Safety
NCT07221877 ·
Phase: Phase 4 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Naperville
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT07288567 ·
Phase: Phase 3 ·
Ages: 13 Years to 17 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
NCT07424404 ·
Phase: Phase 3 ·
Ages: 5 Years to 17 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT07061288 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
NCT06740383 ·
Phase: Not specified ·
Ages: 18 Years to 40 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
CLOZAPINE Response in Biotype-1
NCT04580134 ·
Phase: Phase 4 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Crystal Lake, Warrenville
-
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
NCT07101094 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Illinois: Evanston
-
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Randomized Withdrawal Study in Patients With Schizophrenia
NCT06961968 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCT05184335 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCT06229210 ·
Phase: Phase 3 ·
Ages: 5 Years to 17 Years ·
Sex: All (male and female)
· Illinois: Naperville
-
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964 ·
Phase: Phase 2 ·
Ages: 21 Years to 55 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
NCT07467993 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
NCT07363577 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Illinois: Chicago
-
Transition Care for FEP
NCT07713849 ·
Phase: Not specified ·
Ages: 18 Years to 40 Years ·
Sex: All (male and female)
· Illinois: Chicago, Harvey